secwatch.observer — SEC 8-K summary
======================================

Issuer:     Axsome Therapeutics, Inc. (AXSM)
CIK:        0001579428
Form:       8-K
Filed at:   2024-10-01T23:59:59+00:00
Accession:  0000950170-24-110957
Event type: debt
Sentiment:  positive
Materiality: 0.55
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Axsome amends Hercules loan: Tranche 3 raised to $80M, covenants eased
----------------------------------------------------------------------

- Fifth Amendment increases Tranche 3 commitment from $75M to $80M.
- Availability periods extended: Tranche 1D to June 15, 2025; Tranche 1E to Dec 15, 2025.
- Performance covenants restructured; new Performance Covenant D added.
- Conditional waiver of $30M+ qualified cash requirement when market cap exceeds $1.5B.
- Malta subsidiary permitted to request advances and hold more cash outside U.S.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024110957/0000950170-24-110957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1579428/000095017024110957/axsm-20240930.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-110957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer